Retrovir — Competitive Intelligence Brief

Retrovir (ZIDOVUDINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]. Area: Immunology.

marketed Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Thymidine kinase, cytosolic Immunology Small molecule

Target snapshot

Retrovir (ZIDOVUDINE) — GSK. Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Retrovir TARGET	ZIDOVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Thymidine kinase, cytosolic	1987-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Tivicay	DOLUTEGRAVIR	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Transmembrane protein 97	2013-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
ABACAVIR SULFATE	ABACAVIR SULFATE		marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		1998-01-01
Epivir	LAMIVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Deoxycytidine kinase	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class)

1. GSK · 3 drugs in this class
2. · 1 drug in this class